Chapter 9 Intellectual property and data privacy in the pharmaceutical sector
-
Rishabha Malviya
Abstract
In the pharmaceutical sector, data privacy is essential to providing quality care. However, protecting large volumes of data has proven to be a difficult mandate, and the healthcare sector is still vulnerable to data breaches that make headlines. Intellectual property rights (IPR) are crucial to the pharmaceutical industry because they allow inventors to legally maintain the confidentiality of their inventions for a predetermined amount of time. The exclusive rights that inventors and creators have to make money off their inventions are known as intellectual property rights or IPRs. These rights are protected under various laws, including patents, copyrights, and trademarks. The chapter also discusses how blockchain technology can be used to manage IPRs and improve patient privacy. It highlights the challenges of data privacy in the pharmaceutical industry, including cybersecurity risks and compliance with data protection laws. In the intricate pharmaceutical supply chain, cooperation between distributors, manufacturers, and other stakeholders is essential for safeguarding data privacy. Overall, the chapter emphasizes the necessity of a balanced approach to data privacy and intellectual property, as well as the intricate and regulated nature of the pharmaceutical industry. It suggests that addressing unfair practices and promoting innovation can contribute to the welfare of consumers and the advancement of society.
Abstract
In the pharmaceutical sector, data privacy is essential to providing quality care. However, protecting large volumes of data has proven to be a difficult mandate, and the healthcare sector is still vulnerable to data breaches that make headlines. Intellectual property rights (IPR) are crucial to the pharmaceutical industry because they allow inventors to legally maintain the confidentiality of their inventions for a predetermined amount of time. The exclusive rights that inventors and creators have to make money off their inventions are known as intellectual property rights or IPRs. These rights are protected under various laws, including patents, copyrights, and trademarks. The chapter also discusses how blockchain technology can be used to manage IPRs and improve patient privacy. It highlights the challenges of data privacy in the pharmaceutical industry, including cybersecurity risks and compliance with data protection laws. In the intricate pharmaceutical supply chain, cooperation between distributors, manufacturers, and other stakeholders is essential for safeguarding data privacy. Overall, the chapter emphasizes the necessity of a balanced approach to data privacy and intellectual property, as well as the intricate and regulated nature of the pharmaceutical industry. It suggests that addressing unfair practices and promoting innovation can contribute to the welfare of consumers and the advancement of society.
Kapitel in diesem Buch
- Frontmatter I
- Preface V
- Foreword VII
- Contents IX
- Chapter 1 Introduction to smart pharma: foundation of AI and big data 1
- Chapter 2 Emerging technology in pharma and the role of AI and blockchain 19
- Chapter 3 Partnership and collaboration in the pharmaceutical industry 37
- Chapter 4 Education and training in smart pharma 55
- Chapter 5 Drug manufacturing and quality control with artificial intelligence 77
- Chapter 6 Drug development and clinical trial via artificial intelligence 97
- Chapter 7 AI-driven clinical decision support systems for pharma executives 121
- Chapter 8 AI-based pharmacovigilance and drug safety 143
- Chapter 9 Intellectual property and data privacy in the pharmaceutical sector 163
- Chapter 10 Regulatory affairs and compliance in the pharmaceutical sector 183
- Chapter 11 AI and big data in post-marketing surveillance 201
- Chapter 12 Challenges and ethical considerations 219
- Chapter 13 Future trends and innovations of AI in healthcare 237
- Index 253
Kapitel in diesem Buch
- Frontmatter I
- Preface V
- Foreword VII
- Contents IX
- Chapter 1 Introduction to smart pharma: foundation of AI and big data 1
- Chapter 2 Emerging technology in pharma and the role of AI and blockchain 19
- Chapter 3 Partnership and collaboration in the pharmaceutical industry 37
- Chapter 4 Education and training in smart pharma 55
- Chapter 5 Drug manufacturing and quality control with artificial intelligence 77
- Chapter 6 Drug development and clinical trial via artificial intelligence 97
- Chapter 7 AI-driven clinical decision support systems for pharma executives 121
- Chapter 8 AI-based pharmacovigilance and drug safety 143
- Chapter 9 Intellectual property and data privacy in the pharmaceutical sector 163
- Chapter 10 Regulatory affairs and compliance in the pharmaceutical sector 183
- Chapter 11 AI and big data in post-marketing surveillance 201
- Chapter 12 Challenges and ethical considerations 219
- Chapter 13 Future trends and innovations of AI in healthcare 237
- Index 253
